Fidelity Investments’s Nephros NEPH Stock Holding History

Fidelity Investments’s Portfolio NEPH Stock Details NEPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-91	Closed	-$1K	–	5305
2021 Q4	$1K	Hold	91	–	–	﹤0.01%	4167
2021 Q3	$1K	Buy	+91	New	+$789	﹤0.01%	4167

Other funds holding NEPH

Bard Associates Chicago, Illinois $451M AUM 66.6% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wexford Capital West Palm Beach, Florida $690M AUM 57.88% 1-Year Est. Return

CPA

Cowen Prime Advisors New York $290M AUM 57.8% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Elkhorn Partners Omaha, Nebraska $117M AUM 28.12% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Cantor Fitzgerald New York $9.23B AUM 74.49% 1-Year Est. Return

Fidelity Investments's NEPH Position: Q1 2022 in Review

Fidelity Investments sold out of Nephros (NEPH) in Q1 2022, closing a stake of 91 shares — an estimated $1K sold.

Fidelity Investments first reported a position in NEPH in Q3 2021 and held it in 2 quarters. The position peaked at $1K in Q4 2021. 16 funds tracked by Wall St. Rank hold NEPH as of Q1 2022.

Fidelity Investments reported no remaining Nephros position as of Q1 2022 after selling out during the quarter.
Fidelity Investments sold 91 Nephros shares in Q1 2022, an estimated $1K.
Fidelity Investments first reported a position in Nephros in Q3 2021 and held it in 2 quarters.
Fidelity Investments's Nephros position peaked at $1K in Q4 2021.
16 funds tracked by Wall St. Rank held Nephros as of Q1 2022.

Based on Fidelity Investments's 13F filing for Q1 2022, filed 13 May 2022.